Loading
Stage Iv Lung Non Small Cell Cancer AJCC V7 / Laboratory Biomarker Analysis / Cabozantinib S-malate · Phase 2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 registration record for a randomized trial comparing erlotinib and cabozantinib monotherapy against combination therapy in stage IV NSCLC patients receiving second or third-line treatment. No efficacy or safety results are reported in this registry entry; the study remains active and outcome data are not yet available for clinical interpretation.
Phase 2, Interventional, Randomized, Crossover, Open label, Treatment purpose. Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7; age from 18 Years. Intervention: Arm A (erlotinib); Arm B (cabozantinib); Arm C (erlotinib+cabozantinib); Arm Z (erlotinib+cabozantinib; step II). Compared with: Three-arm comparison: erlotinib alone vs. cabozantinib alone vs. combination therapy.. n = 125. 356 sites: United States.
This is a Phase 2 registration record for a randomized trial comparing erlotinib and cabozantinib monotherapy against combination therapy in stage IV NSCLC patients receiving second or third-line treatment. No efficacy or safety results are reported in this registry entry; the study remains active and outcome data are not yet available for clinical interpretation.
No results are posted in this registry record; efficacy, safety, and comparisons between arms cannot be assessed.
The source did not state who this applies to in practice.
This is a Phase 2 trial registry record with no results posted; the study is active but not recruiting, and outcome data are not yet reported in this source.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT01708954). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 125 participants (ACTUAL). Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7. Interventions: DRUG: Cabozantinib S-malate; DRUG: Erlotinib Hydrochloride; OTHER: Laboratory Biomarker Analysis. Primary outcome measures: Progression-free Survival (PFS) , Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry, up to 5 years. Brief summary: This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.